Abstract

The REMEDIES (RE-configuring MEDicines End-to-end Supply) project, launched in 2014, is headed up by GlaxoSmithKline (GSK) with research led by the University of Cambridge’s Institute for Manufacturing. It brings together key players in the end-to-end supply chain, including major contract manufacturing organizations, equipment manufacturers along with regulators, knowledge transfer networks, and healthcare providers.

Mission

To provide a better service to patients and to safeguard jobs across the UK, the consortium has several technology-based application projects underpinned by two platform projects: clinical trials supply chains, led by GSK, and commercial supply chains led by IfM. The project involves several inter-related application work streams.

Consortium History
Structure & Governance

The REMEDIES Consortium was developed by GlaxoSmithKline with research being led by the University of Cambridge’s Institute of Manufacturing.

Financing

The consortium is funded with government money and industry contributions.

Links/Social Media Feed

Homepage: https://remediesproject.com/

Points of Contact

Dr. Ettore Settanni, University of Cambridge
E.Settanni@eng.cam.ac.uk

Sponsors & Partners

GlaxoSmithKline
AstraZeneca
University of Cambridge, Institute of Manufacturing
University of Strathclyde
SAP
Robinsons Brothers
C-Tech Innovation
Cambridge Reactor Design
Alconbury Weston Ltd
Blacktrace
Cogent
The Centre for Process Innovation
IntensiChem
Perceptive Engineering
Intersys
Britest
CrystecPharma
GEA Processing Engineering
Mettler-Toledo
Process Systems Engineering (PSE)
Juniper Pharmaceuticals

Updated: 06/27/2017